Presentation will cover new data on the
long-term efficacy of crofelemer (Mytesi®) based on a supplemental
analysis of the ADVENT trial
Napo Pharmaceuticals, Inc., a human health company developing
and commercializing novel gastrointestinal prescription products
from plants used traditionally in rainforest areas, and Jaguar
Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), announced today that
new crofelemer (Mytesi®) data from a supplemental analysis
of the ADVENT trial will be featured in a poster presentation at
the 9th International Aids Society (IAS) Conference on HIV Science.
The meeting will be held from July 23 to 26, 2017 in Paris,
France.
Presentation Title: Long-Term Crofelemer Use Gives Clinically
Relevant Reductions in HIV-Related Diarrhea
Presentation by Roger D. MacArthur, MD, Patrick Clay, PharmD,
Gary Blick, MD, Roger Waltzman, MD, Margie Bell, MS
Date and Time of Presentation: Wednesday, July 26, 2017, 12:30 –
4:30 p.m.
Dates and Time of Poster Display: Monday, July 24 - Wednesday,
July 26, 12:30 – 4:30 p.m.
Location: Poster Exhibition area
Abstract Number: A-854-0101-01472
Launched by Napo Pharmaceuticals in October 2016, Mytesi® is the
only antidiarrheal studied in and U.S. FDA-approved for the
symptomatic relief of noninfectious diarrhea in adults living with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is a prescription
treatment for diarrhea that works differently, by acting locally in
the GI tract to normalize the flow of water. Mytesi® does not have
drug-drug interactions with ART and has side effects that are
similar to placebo.
The IAS Conference on HIV Science features the latest HIV
science, including basic, clinical and prevention research. It
brings together a broad cross section of HIV professionals from
around the world with a focus on implementation – moving scientific
advances into practice.
The poster for Napo’s presentation will be available on the IAS
website in July after the conference begins.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for
the symptomatic relief of noninfectious diarrhea in adult patients
with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is
not indicated for the treatment of infectious diarrhea. Rule out
infectious etiologies of diarrhea before starting Mytesi®.
If infectious etiologies are not considered, there is a risk that
patients with infectious etiologies will not receive the
appropriate therapy and their disease may worsen. In clinical
studies, the most common adverse reactions occurring at a rate
greater than placebo were upper respiratory tract infection (5.7%),
bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased
bilirubin (3.1%).
More information and complete Prescribing Information are
available at Mytesi.com. Crofelemer, the active ingredient in
Mytesi®, is a botanical (plant-based) drug extracted and
purified from the red bark sap of the medicinal Croton lechleri
tree in the Amazon rainforest. Napo has established a sustainable
harvesting program for crofelemer to ensure a high degree of
quality and ecological integrity.
Proposed Merger
As announced March 31, 2017, Napo and Jaguar Animal Health, Inc.
have entered a definitive merger agreement. The proposed merger of
Jaguar and Napo remains subject to customary conditions to closing.
Upon the consummation of the merger, Jaguar’s name will be changed
to Jaguar Health, Inc., and Napo will operate as a wholly-owned
subsidiary of Jaguar, focused on human health. As previously
stated, Jaguar and Napo expect the merger to close by the end of
July 2017.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc., focuses on the
development and commercialization of proprietary pharmaceuticals
from rainforest resources for the global marketplace in
collaboration with local partners.
For more information, please visit www.napopharma.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused
on developing and commercializing first-in-class gastrointestinal
products for companion and production animals, foals, and high
value horses. Canalevia™ is Jaguar’s lead prescription drug product
candidate, intended for the treatment of various forms of diarrhea
in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s
prescription drug product candidate for the treatment of
gastrointestinal ulcers in horses. Canalevia™ and Equilevia™
contain ingredients isolated and purified from the Croton lechleri
tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™
Foal are Jaguar’s lead non-prescription products. Neonorm™ is a
standardized botanical extract derived from the Croton lechleri
tree. Canalevia™ and Neonorm™ are distinct products that act at the
same last step in a physiological pathway generally present in
mammals. Jaguar has nine active investigational new animal drug
applications, or INADs, filed with the FDA and intends to develop
species-specific formulations of Neonorm™ in six additional target
species, formulations of Equilevia™ in horses, and Canalevia™ for
cats and dogs.
For more information about Jaguar, please visit
www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
the proposed merger between Jaguar and Napo, the expectation that
the proposed merger will close by the end of July 2017, Jaguar’s
intention to develop species-specific formulations of Neonorm™ in
additional target species, and Jaguar’s plan to develop
formulations of Canalevia™ for cats, horses and dogs. In some
cases, you can identify forward-looking statements by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this release are only predictions. Jaguar has based
these forward-looking statements largely on its current
expectations and projections about future events. These
forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and
some of which are beyond Jaguar’s control. Except as required by
applicable law, Jaguar does not plan to publicly update or revise
any forward-looking statements contained herein, whether as a
result of any new information, future events, changed circumstances
or otherwise.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170627005820/en/
KCSA Strategic CommunicationsKate Tumino,
212-896-1252ktumino@kcsa.comorLisa Lipson,
508-843-6428llipson@kcsa.com
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Sep 2023 to Sep 2024